As of November 8, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of PMV Pharmaceuticals, Inc. The largest reported stake is BML Investment Partners, L.P.'s, at 9.9%. 13 filings are on record since August 13, 2025 (Schedule 13G/A, February 9, 2026).
Sell to companies like PMV Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Samsara BioCapital, L.P. · Sole voting: 0 · Shared voting: 3,788,734 · Sole dispositive: 0 · Shared dispositive: 3,788,734 · SCHEDULE 13G, 2026-09-15
- · Reporting person: Sio Capital Management, LLC · Sole voting: 0 · Shared voting: 2,634,137 · Sole dispositive: 0 · Shared dispositive: 2,634,137 · SCHEDULE 13G/A, 2026-07-28
- · Reporting person: ArrowMark Colorado Holdings, LLC · Sole voting: 1,959,579 · Shared voting: 0 · Sole dispositive: 1,959,579 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-10
- · Holder: Euclidean Capital LLC · Percent: 4.9% · SCHEDULE 13G/A
- · Holder: Sio Capital Management, LLC · Percent: 5.77% · SCHEDULE 13G/A
PMV Pharmaceuticals, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-13. 3 holders' latest filing reports 5% or more of common stock, $0.00001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.9% | 5,292,000 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-31 |
| 9.9% | 7,577,467 | SCHEDULE 13G, 2026-09-15 | 2026-09-02 | |
| Tang Capital Management, LLC | 8.9% | 4,720,357 | SCHEDULE 13G, 2025-09-23 | 2025-09-16 |
| Sio Capital Management, LLC | 4.94% | 2,634,137 | SCHEDULE 13G/A, 2026-07-28 | 2026-06-30 |
| Euclidean Capital LLC | 4.9% | 2,627,643 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| ArrowMark Colorado Holdings, LLC | 3.67% | 1,959,579 | SCHEDULE 13G/A, 2026-07-10 | 2026-06-30 |
| PFM Health Sciences, LP | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Orbimed Advisors LLC | 0% | 0 | SCHEDULE 13D/A, 2026-03-04 | 2026-03-02 |
Holding shares or following this stake? See who's behind PMV Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on PMV Pharmaceuticals, Inc. and the records around it.
PMV Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Oct 2026
- Who owns it
Companies that share a holder
- PFM Health Sciences, LP also filed stake reports on 2 other companies: Outset Medical, Inc. (Feb 2026), Werewolf Therapeutics, Inc. (Aug 2025)
- ArrowMark Colorado Holdings, LLC also filed stake reports on 9 other companies: Sprout Social, Inc. (Apr 2026), CIMPRESS plc (Feb 2026), ZIFF DAVIS, INC. (Feb 2026)
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), Anteris Technologies Global Corp. (May 2026)
Watch PMV Pharmaceuticals, Inc.
Get an email when PMV Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on PMV Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on PMV Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PMV Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 0 | 3,788,734 | 0 | 3,788,734 | SCHEDULE 13G, 2026-09-15 |
| Samsara BioCapital GP, LLC | 0 | 3,788,734 | 0 | 3,788,734 | SCHEDULE 13G, 2026-09-15 |
| Samsara Opportunity Fund, L.P. | 0 | 3,788,733 | 0 | 3,788,733 | SCHEDULE 13G, 2026-09-15 |
| Samsara Opportunity Fund GP, LLC | 0 | 3,788,733 | 0 | 3,788,733 | SCHEDULE 13G, 2026-09-15 |
| Srinivas Akkaraju | 0 | 7,577,467 | 0 | 7,577,467 | SCHEDULE 13G, 2026-09-15 |
| Sio Capital Management, LLC | 0 | 2,634,137 | 0 | 2,634,137 | SCHEDULE 13G/A, 2026-07-28 |
| ArrowMark Colorado Holdings, LLC | 1,959,579 | 0 | 1,959,579 | 0 | SCHEDULE 13G/A, 2026-07-10 |
The latest filing identifies PMV Pharmaceuticals, Inc. by CUSIP 69353Y103 and gives its principal executive office as 400 Alexander Park Drive, Suite 301, PRINCETON, NJ 08540 (SCHEDULE 13G, 2026-09-15).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.Srinivas Akkaraju, SCHEDULE 13G, 2026-09-15
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-04; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Sio Capital Management, LLC | 7.19% | SCHEDULE 13G/A |
| 2025-08-14 | PFM Health Sciences, LP | 0% | SCHEDULE 13G/A |
| 2025-09-23 | Tang Capital Management, LLC | 8.9% | SCHEDULE 13G |
| 2025-10-27 | Orbimed Advisors LLC | 9.4% | SCHEDULE 13D/A |
| 2025-11-12 | Sio Capital Management, LLC | 4.98% | SCHEDULE 13G/A |
| 2026-02-09 | BML Investment Partners, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | ArrowMark Colorado Holdings, LLC | 5.81% | SCHEDULE 13G/A |
| 2026-03-04 | Orbimed Advisors LLC | 0% | SCHEDULE 13D/A |
| 2026-05-04 | Sio Capital Management, LLC | 5.77% | SCHEDULE 13G/A |
| 2026-05-15 | Euclidean Capital LLC | 4.9% | SCHEDULE 13G/A |
| 2026-07-10 | ArrowMark Colorado Holdings, LLC | 3.67% | SCHEDULE 13G/A |
| 2026-07-28 | Sio Capital Management, LLC | 4.94% | SCHEDULE 13G/A |
| 2026-09-15 | Srinivas Akkaraju | 9.9% | SCHEDULE 13G |
Questions about who owns PMV Pharmaceuticals, Inc.
Who owns PMV Pharmaceuticals, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of PMV Pharmaceuticals, Inc.: BML Investment Partners, L.P. (9.9%, Schedule 13G/A, filed 2026-02-09), Srinivas Akkaraju (9.9%, Schedule 13G, filed 2026-09-15) and Tang Capital Management, LLC (8.9%, Schedule 13G, filed 2025-09-23).
Who are the largest shareholders of PMV Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of PMV Pharmaceuticals, Inc. on this page are BML Investment Partners, L.P. (9.9%), Srinivas Akkaraju (9.9%) and Tang Capital Management, LLC (8.9%).
When did BML Investment Partners, L.P. buy into PMV Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BML Investment Partners, L.P. on this page is the Schedule 13G/A, filed 2026-02-09, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for PMV Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 5, 2026 | Leadership change: Matthew Eckler appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for PMV Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.